- Home
- SLM vs AXSM Comparison
SLM vs AXSM Comparison
Compare SLM & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- AXSM
- Stock Information
- Founded
- SLM 1972
- AXSM 2012
- Country
- SLM United States
- AXSM United States
- Employees
- SLM N/A
- AXSM N/A
- Industry
- SLM Finance: Consumer Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- SLM Finance
- AXSM Health Care
- Exchange
- SLM Nasdaq
- AXSM Nasdaq
- Market Cap
- SLM 4.6B
- AXSM 4.7B
- IPO Year
- SLM N/A
- AXSM 2015
- Fundamental
- Price
- SLM $27.79
- AXSM $90.73
- Analyst Decision
- SLM Buy
- AXSM Strong Buy
- Analyst Count
- SLM 10
- AXSM 14
- Target Price
- SLM $27.10
- AXSM $125.93
- AVG Volume (30 Days)
- SLM 3.5M
- AXSM 499.7K
- Earning Date
- SLM 01-22-2025
- AXSM 02-18-2025
- Dividend Yield
- SLM 1.87%
- AXSM N/A
- EPS Growth
- SLM 117.36
- AXSM N/A
- EPS
- SLM 2.91
- AXSM N/A
- Revenue
- SLM $1,586,141,000.00
- AXSM $338,457,000.00
- Revenue This Year
- SLM N/A
- AXSM $44.89
- Revenue Next Year
- SLM $7.55
- AXSM $68.41
- P/E Ratio
- SLM $9.57
- AXSM N/A
- Revenue Growth
- SLM 46.87
- AXSM 51.47
- 52 Week Low
- SLM $18.04
- AXSM $64.11
- 52 Week High
- SLM $28.24
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- SLM 63.32
- AXSM 42.16
- Support Level
- SLM $26.64
- AXSM $89.09
- Resistance Level
- SLM $27.40
- AXSM $94.64
- Average True Range (ATR)
- SLM 0.75
- AXSM 3.64
- MACD
- SLM -0.04
- AXSM -1.14
- Stochastic Oscillator
- SLM 81.42
- AXSM 20.64
About SLM SLM Corporation
SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.